Bowling Portfolio Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Bowling Portfolio Management’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-127,873	Closed	-$1.43M	–	448
2017 Q3	$1.43M	Buy	+127,873	New	+$1.41M	0.22%	157
2017 Q2	–	Sell	-68,473	Closed	-$671K	–	435
2017 Q1	$671K	Buy	68,473 +8,810	+15%	+$88K	0.11%	226
2016 Q4	$644K	Buy	59,663 +45,078	+309%	+$451K	0.1%	193
2016 Q3	$149K	Buy	+14,585	New	+$159K	0.02%	295
2016 Q2	–	Sell	-17,463	Closed	-$192K	–	188
2016 Q1	$192K	Buy	+17,463	New	+$155K	0.03%	156

Bowling Portfolio Management's SCLN Position: Q4 2017 in Review

Bowling Portfolio Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 127,873 shares — an estimated $1.43M sold.

Bowling Portfolio Management first reported a position in SCLN in Q1 2016 and held it in 5 quarters. The position peaked at $1.43M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Bowling Portfolio Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Bowling Portfolio Management sold 127,873 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.43M.
Bowling Portfolio Management first reported a position in Sciclone Pharmaceuticals Inc in Q1 2016 and held it in 5 quarters.
Bowling Portfolio Management's Sciclone Pharmaceuticals Inc position peaked at $1.43M in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Bowling Portfolio Management's 13F filing for Q4 2017, filed 22 Jan 2018.